MNOV
MediciNova
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
consensus rating "Strong Buy"
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About MNOV
Medicinova, Inc.
A biopharmaceutical company developing products primarily focused on neurology, respiratory
Biological Technology
09/26/2000
12/07/2006
NASDAQ Stock Exchange
13
12-31
Common stock
4275 Executive Square
, Suite 300
, La Jolla
, CA 92037
--
MediciNova, Inc., was incorporated in Delaware on September 26, 2000. In December 2009, it acquired a biopharmaceutical company called Avigen Inc., which focuses on finding and developing differentiated products to treat patients with severe disorders. The company's product candidates are for inhibiting cell movement and glial attenuators in the macrophage central nervous system, such as neuropathic pain, opioid addiction and withdrawal, and physical disorders such as methamphetamine addiction.
MediciNova, Inc., is a developing biopharmaceutical company focused on acquiring and developing novel small molecule therapies to treat serious and specific diseases with unmet medical needs in the US market. Through strategic alliances, mainly with Japanese pharmaceutical companies, the company has an ownership interest in a diverse range of clinical and preclinical product candidates and believes that this will provide the company with significant business opportunities.
Company Financials
EPS
MNOV has released its 2024 Q4 earnings. EPS was reported at -0.06, versus the expected -0.05, missing expectations. The chart below visualizes how MNOV has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available